

Comparing Two Versions of Application

Study Dashboard

PRISM

Carilion Clinic

Account: Hilary Hedrick
Department: CC - Institutional Review Board
Path: [Home](#) > [find study](#)

Help

My Profile

Log out

My Workspaces

IRB Number: **IRB-19-344**
Study Alias: test
PI: Blevins, Brooke

IRB: Committee A

Submissions

Back

Study Status: **With Research Team for Corrections**

IRB Number : IRB-19-344

Study Title : HSRx

IRB Expiration Date: 04/15/2025

Submissions

Study Management

Protocol Items

Study Application

Informed Consents

Other Study Documents

Initial

Initial

Initial Review Submission Packet

Post-Approval Forms

Annual Check-In Form (for Minimal Risk studies approved with Annual Check-In after 1/20/19)

Carilion Clinic - Conclusion Form

Carilion Clinic - Continuing Review Form

Carilion Clinic - Promptly Reportable Information Form

Carilion Clinic - Research Change / Update Form

Submissions History

Study Correspondence

Track Location	Ref Number	Request Type	Process Submission
There are no outstanding submissions.			

Click this button to go to applications.

Study applications

PRISM

Carilion Clinic

Account: Hilary Hedrick

Department: CC - Institutional Review Board

Path: [Home](#) > [find study](#) > [study mgmt.](#)

My Workspaces

IRB Number: **IRB-19-344**

Study Alias: test

PI: Blevins, Brooke

IRB: Committee A

Study Application

Study Status: With Research Team for Corrections

IRB Number : IRB-19-344

Study Title : HSRx

IRB Expiration Date: 04/15/2025

1 result(s) found...

Compare Two Selected Versions

	Show Rev.	Edit/View	Study Application	Approved	Approval Date	Created By	Date Created	Last Modified By	Last Date Modified
☐			Carilion IRB Application (Version 1.3)	No		Brooke Blevins	03-06-2024 15:20	Brooke Blevins	03-06-2024 15:20

Click this folder button to view all versions of applications.

Application Versions

PRISM

Carilion Clinic

Account: Hilary Hedrick
Department: CC - Institutional Review Board
Path: [Home](#) > [find study](#) > [study mgmt.](#)

My Workspaces

IRB Number: **IRB-19-344**
Study Alias: test
PI: Blevins, Brooke

IRB: Committee A

Study Application

Back

Study Status: **With Research Team for Corrections**

IRB Number : IRB-19-344

Study Title : HSRx

IRB Expiration Date: 04/15/2025

1 result(s) found...

	Show Rev.	Edit/ View	Study Application	Approved	Approval Date	Created By	Date Created	Last Modified By	Last Date Modified
☒			Carilion IRB Application (Version 1.3)	No		Brooke Blevins	03-06-2024 15:20	Brooke Blevins	03-06-2024 15:20
☒			Carilion IRB Application (Version 1.1)	No		Brooke Blevins	09-12-2022 09:46	Brooke Blevins	09-12-2022 09:46
☐			Carilion IRB Application (Version 1.0)	No		Carley Emerson	02-18-2019 15:04	Carley Emerson	01-21-2021 13:04

Compare Two Selected Versions

Click this button to compare the two application versions you selected.

Choose by checking the two boxes for the versions you want to compare.

Comparison Screen

The two versions of application will appear side-by-side in a pop-out screen. The **most recent changes will be highlighted in green** and **red shows what was removed from previous application version.**

Version: 1.1
Brooke Blevins

Carilion IRB Application

Version: 1.3
Brooke Blevins

Section	Version 1.1	Version 1.3
3.1 -	Section 3 - Grant Key Personnel access to the study 3.1 - Please add a Principal Investigator for the study Tanner Harmon	Section 3 - Grant Key Personnel access to the study 3.1 - Please add a Principal Investigator for the study Tanner Harmon Brooke Blevins
3.3 -	Section 3 - Grant Key Personnel access to the study 3.3 - Please add a Study Contact 01. Tanner Harmon	Section 3 - Grant Key Personnel access to the study 3.3 - Please add a Project Contact: 01. Tanner Harmon Brooke Blevins
5.1 -	Not Defined in Version 1.1	Section 5 - Application Type 5.1 - IRB-19-344
7.1 -	Section 7 - Regulatory Compliance 7.1 - How many studies is the PI currently responsible for? 2	Section 7 - Regulatory Compliance 7.1 - How many studies is the PI currently responsible for? 2
7.2 -	Section 7 - Regulatory Compliance 7.2 - Does the PI have protected or dedicated time available to conduct this research? ☐ Yes ☐ No	Section 7 - Regulatory Compliance 7.2 - Does the PI have protected or dedicated time available to conduct this research? ☐ Yes ☒ No ☐ Yes ☐ No
7.3 -	Section 7 - Regulatory Compliance 7.3 - Has any member of the research team ever received a FDA 483, "Warning Letter", Notice of Disqualification, or other warning or disciplinary action from an agency or licensing authority? ☐ Yes ☐ No	Section 7 - Regulatory Compliance 7.3 - Has any member of the research team ever received a FDA 483, "Warning Letter", Notice of Disqualification, or other warning or disciplinary action from an agency or licensing authority? ☐ Yes ☒ No ☐ Yes ☐ No
7.4 -	Section 7 - Regulatory Compliance 7.4 - Has this study been disapproved or terminated by another IRB? ☐ Yes ☐ No	Section 7 - Regulatory Compliance 7.4 - Has this study been disapproved or terminated by another IRB? ☐ Yes ☒ No ☐ Yes ☐ No
10.1 -	Section 10 - Human Subjects Research Description 10.1 - In the opinion of the Principal Investigator, does this research impart minimal risk or greater than minimal risk to subjects? <i>As defined by regulation, minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Please note that the IRB makes the final determination of risk level and may ask you to change this based on their decision.</i> <i>If this is a Conversion of a Paper Application, select the risk level that has been determined already by the IRB at most recent review per the most recent approval letter (expedited review = minimal risk, full board review = greater than minimal risk).</i> ☒ Minimal Risk ☐ Greater than minimal	Section 10 - Human Subjects Research Description 10.1 - In the opinion of the Principal Investigator, does this research impart minimal risk or greater than minimal risk to subjects? <i>As defined by regulation, minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Please note that the IRB makes the final determination of risk level and may ask you to change this based on their decision.</i> <i>If this is a Conversion of a Paper Application, select the risk level that has been determined already by the IRB at most recent review per the most recent approval letter (expedited review = minimal risk, full board review = greater than minimal risk).</i> ☒ Minimal Risk ☐ Greater than minimal
10.2 -	Not Defined in Version 1.1	Section 10 - Human Subjects Research Description 10.2 - Does the research offer the prospect of direct benefits to the individual subjects?

These arrows will help you navigate through applications to compare different sections of application with changes identified.

Print Close

*You can also get to comparison screen from stipulation response form.

Pre-Review Correction Form

My Workspaces ☒ IRB Number: **IRB-19-344** Study Alias: test PI: Blevins, Brooke Study Assistant Pre-Review Correction Form - (Version 4.0) [Back](#)

[Print Friendly](#) [Refresh Constant Fields](#) [Save Section](#) [Save and Continue to Next Section](#)

Section view of the Form **Entire view of the Form**

1.0 [Pre-Review Response Form](#)
2.0 [Requested Revisions and Comments](#)

Comments That Must Be Addressed With Follow-up Deadlines:

No Stipulation entered.

Comments:

No Stipulation entered.

Show submission component(s) in round: **4 Current Round** [Items in Folder View](#) [Add New Component](#) [Compare Item\(s\)](#) [Create PDF Packet](#)

Compare	Include in PDF Packet	Compare to Last Approved	View in Separate Window	Unattach	Revise/Attach	All Submission Components Previous Rounds & Currently Attached
Submission Form(s)						
☐	☐					Carilion Clinic IRB - Pre-Review Correction Form - (Version 4.0 (Incomplete))
☐	☐					Initial Review Submission Packet - (Version 1.0)
Application						
☒	☐					Carilion IRB Application - (Version 1.4 (Incomplete))
☒	☐					Carilion IRB Application - (Version 1.3)
☐	☐					Carilion IRB Application - (Version 1.2)
Consent Form(s)						
Category : Consent						
☐	☐					Consent (English) - (Version 1.3)
Document(s)						
Category : Consent documents						
☐	☐					CONSENT_DOCUMENT_for_testing - (Version 1.0)
Category : Grant Application						
☐	☐					HRP-804 INVESTIGATOR GUIDANCE - Electronic Informed Consent ORIGINAL WORD - (Version 1.0)

Click this button to compare the two application versions you selected.

Choose by checking the two boxes for the versions you want to compare.

Comparison Screen

The two versions of application will appear side-by-side in a pop-out screen. The **most recent changes will be highlighted in green** and **red shows what was removed from previous application version.**

Version: 1.1
Brooke Blevins

Carilion IRB Application

Version: 1.3
Brooke Blevins

Section	Version 1.1	Version 1.3
3.1 -	Section 3 - Grant Key Personnel access to the study 3.1 - Please add a Principal Investigator for the study Tanner Harmon	Section 3 - Grant Key Personnel access to the study 3.1 - Please add a Principal Investigator for the study Tanner Harmon Brooke Blevins
3.3 -	Section 3 - Grant Key Personnel access to the study 3.3 - Please add a Study Contact 01. Tanner Harmon	Section 3 - Grant Key Personnel access to the study 3.3 - Please add a Project Contact: 01. Tanner Harmon Brooke Blevins
5.1 -	Not Defined in Version 1.1	Section 5 - Application Type 5.1 - IRB-19-344
7.1 -	Section 7 - Regulatory Compliance 7.1 - How many studies is the PI currently responsible for? 2	Section 7 - Regulatory Compliance 7.1 - How many studies is the PI currently responsible for? 2
7.2 -	Section 7 - Regulatory Compliance 7.2 - Does the PI have protected or dedicated time available to conduct this research? ☐ Yes ☐ No	Section 7 - Regulatory Compliance 7.2 - Does the PI have protected or dedicated time available to conduct this research? ☐ Yes ☒ No ☐ Yes ☐ No
7.3 -	Section 7 - Regulatory Compliance 7.3 - Has any member of the research team ever received a FDA 483, "Warning Letter", Notice of Disqualification, or other warning or disciplinary action from an agency or licensing authority? ☐ Yes ☐ No	Section 7 - Regulatory Compliance 7.3 - Has any member of the research team ever received a FDA 483, "Warning Letter", Notice of Disqualification, or other warning or disciplinary action from an agency or licensing authority? ☐ Yes ☒ No ☐ Yes ☐ No
7.4 -	Section 7 - Regulatory Compliance 7.4 - Has this study been disapproved or terminated by another IRB? ☐ Yes ☐ No	Section 7 - Regulatory Compliance 7.4 - Has this study been disapproved or terminated by another IRB? ☐ Yes ☒ No ☐ Yes ☐ No
10.1 -	Section 10 - Human Subjects Research Description 10.1 - In the opinion of the Principal Investigator, does this research impart minimal risk or greater than minimal risk to subjects? <i>As defined by regulation, minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Please note that the IRB makes the final determination of risk level and may ask you to change this based on their decision.</i> <i>If this is a Conversion of a Paper Application, select the risk level that has been determined already by the IRB at most recent review per the most recent approval letter (expedited review = minimal risk, full board review = greater than minimal risk).</i> ☒ Minimal Risk ☐ Greater than minimal	Section 10 - Human Subjects Research Description 10.1 - In the opinion of the Principal Investigator, does this research impart minimal risk or greater than minimal risk to subjects? <i>As defined by regulation, minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests. Please note that the IRB makes the final determination of risk level and may ask you to change this based on their decision.</i> <i>If this is a Conversion of a Paper Application, select the risk level that has been determined already by the IRB at most recent review per the most recent approval letter (expedited review = minimal risk, full board review = greater than minimal risk).</i> ☒ Minimal Risk ☐ Greater than minimal
10.2 -	Not Defined in Version 1.1	Section 10 - Human Subjects Research Description 10.2 - Does the research offer the prospect of direct benefits to the individual subjects?

These arrows will help you navigate through applications to compare different sections of application with changes identified.

Print Close